Aclaris Therapeutics (NASDAQ: ACRS) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Aclaris Therapeutics to similar companies based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, risk, dividends and profitability.
This table compares Aclaris Therapeutics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Aclaris Therapeutics Competitors||-5,489.25%||-451.68%||-42.65%|
Valuation and Earnings
This table compares Aclaris Therapeutics and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Aclaris Therapeutics||N/A||-$49.56 million||-12.42|
|Aclaris Therapeutics Competitors||$260.16 million||$66.28 million||-6.36|
Aclaris Therapeutics’ competitors have higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Aclaris Therapeutics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics’ competitors have a beta of 6.62, suggesting that their average stock price is 562% more volatile than the S&P 500.
Institutional and Insider Ownership
95.8% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 50.4% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.3% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 16.4% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a breakdown of current ratings and target prices for Aclaris Therapeutics and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Aclaris Therapeutics Competitors||765||3044||11232||227||2.72|
Aclaris Therapeutics presently has a consensus price target of $41.25, suggesting a potential upside of 63.56%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.87%. Given Aclaris Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Aclaris Therapeutics is more favorable than its competitors.
Aclaris Therapeutics beats its competitors on 7 of the 12 factors compared.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company’s drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.
What are top analysts saying about Aclaris Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aclaris Therapeutics Inc. and related companies.